- JP-listed companies
- Balance sheet
(219A) Balance sheet
Market cap
¥39.8B
P/E ratio
-18.7x
Heartseed develops regenerative heart muscle therapies using iPS cell-derived cardiac spheres to treat severe heart failure patients through medical institutions worldwide.
| 2021/10 | 2022/10 | 2023/10 | 2024/10 | 2025/10 | 2025/12 | |
| Cash and cash equivalents | - | 3,988 | 4,588 | 5,297 | 7,340 | 6,836 |
| Total cash & short-term investments | - | 3,988 | 4,588 | 5,297 | 7,340 | 6,836 |
| Total current assets | - | 4,919 | 5,028 | 6,404 | 7,599 | 7,144 |
| Property, plant and equipment, net | - | 7 | 484 | 456 | 439 | 431 |
| Total non-current assets | - | 17 | 692 | 664 | 540 | 532 |
| Total assets | - | 4,936 | 5,720 | 7,068 | 8,139 | 7,676 |
| Total current liabilities | - | 142 | 244 | 282 | 411 | 320 |
| Total non-current liabilities | - | 66 | 206 | 162 | 160 | 161 |
| Total liabilities | - | 208 | 450 | 444 | 571 | 481 |
| Retained earnings | - | -1,491 | -2,965 | -2,770 | -2,177 | -2,579 |
| Stockholders' equity | 6,140 | 4,728 | 5,270 | 6,623 | 7,568 | 7,195 |